News

Newron presents 2025 financial results and provides 2026 outlook

Ad hoc announcement pursuant to Art. 53 LR Milan, Italy, and Morristown, NJ, USA – March 24, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5

Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

Presentations explore the role of glutamatergic modulation in treatment-resistant schizophrenia (TRS) across preclinical and clinical research   Milan, Italy, and Morristown

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract

Ad hoc announcement pursuant to Art. 53 LR Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance

Newron announces nominations to its Board of Directors at upcoming Annual General Meeting

George Garibaldi and Paolo Zocchi proposed as new independent, non-executive Board members Patrick Langlois and Luca Benatti to step down after long-standing service Full Annual

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program

Ad hoc announcement pursuant to Art. 53 LR Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

Milan, Italy, and Morristown, NJ, USA, January 7, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

Ad hoc announcement pursuant to Art. 53 LR EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being